Kelsey E. Huntington

706 total citations
35 papers, 297 citations indexed

About

Kelsey E. Huntington is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Kelsey E. Huntington has authored 35 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in Kelsey E. Huntington's work include Cancer Immunotherapy and Biomarkers (12 papers), Colorectal Cancer Treatments and Studies (4 papers) and Wnt/β-catenin signaling in development and cancer (4 papers). Kelsey E. Huntington is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Colorectal Cancer Treatments and Studies (4 papers) and Wnt/β-catenin signaling in development and cancer (4 papers). Kelsey E. Huntington collaborates with scholars based in United States, Japan and France. Kelsey E. Huntington's co-authors include Wafik S. El‐Deiry, Lindsey Carlsen, Lanlan Zhou, Anna D. Louie, Benedito A. Carneiro, Olin D. Liang, Jack A. Elias, Chun Geun Lee, Attila A. Seyhan and Shengliang Zhang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Kelsey E. Huntington

30 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kelsey E. Huntington United States 12 129 100 91 47 35 35 297
Elke Malenke Germany 9 126 1.0× 82 0.8× 92 1.0× 31 0.7× 22 0.6× 13 303
Adi Nagler Israel 9 212 1.6× 103 1.0× 121 1.3× 39 0.8× 59 1.7× 11 369
Hanxi Xiao United States 10 109 0.8× 82 0.8× 167 1.8× 23 0.5× 47 1.3× 19 309
Heng Yang China 10 178 1.4× 186 1.9× 104 1.1× 33 0.7× 49 1.4× 16 389
Zhenling Ma China 11 162 1.3× 132 1.3× 120 1.3× 32 0.7× 55 1.6× 23 384
Yanghong Ni China 8 148 1.1× 140 1.4× 108 1.2× 34 0.7× 67 1.9× 9 328
Imène Hamaidi United States 8 168 1.3× 80 0.8× 117 1.3× 41 0.9× 57 1.6× 9 328
Shuangshuang Lu China 12 143 1.1× 133 1.3× 49 0.5× 46 1.0× 71 2.0× 31 338
Simon Milette Canada 10 159 1.2× 146 1.5× 107 1.2× 44 0.9× 64 1.8× 14 392
Zhengang Qiu China 7 142 1.1× 97 1.0× 69 0.8× 73 1.6× 42 1.2× 22 287

Countries citing papers authored by Kelsey E. Huntington

Since Specialization
Citations

This map shows the geographic impact of Kelsey E. Huntington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelsey E. Huntington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelsey E. Huntington more than expected).

Fields of papers citing papers by Kelsey E. Huntington

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelsey E. Huntington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelsey E. Huntington. The network helps show where Kelsey E. Huntington may publish in the future.

Co-authorship network of co-authors of Kelsey E. Huntington

This figure shows the co-authorship network connecting the top 25 collaborators of Kelsey E. Huntington. A scholar is included among the top collaborators of Kelsey E. Huntington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelsey E. Huntington. Kelsey E. Huntington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huntington, Kelsey E., Anna D. Louie, Christoph Schorl, et al.. (2023). GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. International Journal of Molecular Sciences. 24(13). 10870–10870. 11 indexed citations
2.
Yao, Hongwei, Joselynn Wallace, Abigail L. Peterson, et al.. (2023). Timing and cell specificity of senescence drives postnatal lung development and injury. Nature Communications. 14(1). 273–273. 25 indexed citations
3.
Huntington, Kelsey E., et al.. (2023). Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis.. PubMed. 13(1). 307–325. 7 indexed citations
4.
Carlsen, Lindsey, Kelsey E. Huntington, Vida Tajiknia, et al.. (2023). Abstract 6706: Co-culture of circulating tumor cells (CTCs)-derived 3D organoids and autologous cytotoxic CD8+ T cells: A new functional precision oncology platform. Cancer Research. 83(7_Supplement). 6706–6706.
5.
El‐Deiry, Wafik S., Kelsey E. Huntington, Anna D. Louie, et al.. (2023). GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.. Journal of Clinical Oncology. 41(16_suppl). e15138–e15138.
6.
7.
MacDonald, William, et al.. (2023). Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1.. PubMed. 13(7). 2938–2947. 2 indexed citations
8.
9.
George, Andrew, Vida Tajiknia, Yiqun Zhang, et al.. (2023). Therapeutic targeting of TRAIL death receptors. Biochemical Society Transactions. 51(1). 57–70. 25 indexed citations
10.
11.
Uruchurtu, Ashley Sanchez Sevilla, Kelsey E. Huntington, Andrew George, et al.. (2023). Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer. Current Oncology. 30(11). 9611–9626. 4 indexed citations
12.
Hsu, Andrew, Kelsey E. Huntington, André De Souza, et al.. (2022). Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. Cancer Biology & Therapy. 23(1). 417–423. 12 indexed citations
13.
Carlsen, Lindsey, Kelsey E. Huntington, & Wafik S. El‐Deiry. (2022). Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers. Cancers. 14(4). 1028–1028. 38 indexed citations
14.
Maeda, Hajime, Hongwei Yao, Hayato Go, et al.. (2022). Involvement of miRNA-34a regulated Krüppel-like factor 4 expression in hyperoxia-induced senescence in lung epithelial cells. Respiratory Research. 23(1). 340–340. 8 indexed citations
15.
Huntington, Kelsey E., et al.. (2021). SHP-2 deletion in CD4Cre expressing chondrocyte precursors leads to tumor development with wrist tropism. Scientific Reports. 11(1). 20006–20006. 4 indexed citations
16.
Kamle, Suchitra, Bing Ma, Chuan He, et al.. (2021). Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19. JCI Insight. 6(21). 24 indexed citations
17.
Carlsen, Lindsey, et al.. (2021). Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.. PubMed. 11(12). 6086–6106. 12 indexed citations
18.
Louie, Anna D., Kelsey E. Huntington, Lindsey Carlsen, Lanlan Zhou, & Wafik S. El‐Deiry. (2021). Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. Frontiers in Pharmacology. 12. 747194–747194. 29 indexed citations
19.
Carlsen, Lindsey, Christoph Schorl, Kelsey E. Huntington, et al.. (2021). Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells. Oncotarget. 12(20). 2006–2021. 13 indexed citations
20.
Şahin, İlyas, Andrew George, Shengliang Zhang, et al.. (2021). Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget. 12(21). 2131–2146. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elke Malenke Breakdown of academic impact, for papers by Adi Nagler Breakdown of academic impact, for papers by Hanxi Xiao Breakdown of academic impact, for papers by Heng Yang Breakdown of academic impact, for papers by Zhenling Ma Breakdown of academic impact, for papers by Yanghong Ni Breakdown of academic impact, for papers by Imène Hamaidi Breakdown of academic impact, for papers by Shuangshuang Lu Breakdown of academic impact, for papers by Simon Milette Breakdown of academic impact, for papers by Zhengang Qiu
Rankless by CCL
2026